Clinical trials for developing treatment and early diagnostic methods for chronic active antibody-mediated rejection in kidney transplantation —A review
A review highlights methods for diagnosing chronic active antibody-mediated rejection in kidney transplant patients, indicating a need for effective treatments.
Key Points
The majority of long-term kidney transplant failures are due to chronic active antibody-mediated rejection (CAAMR).
Current research aims at identifying biomarkers in blood and urine for early diagnosis of CAAMR.
Various therapeutic approaches have been explored, but no effective treatment for CAAMR has been established.
The need for new diagnostic methods to enhance early detection of CAAMR is crucial as existing methods focus mainly on acute rejection.